What are the recommended pharmacologic treatments for primary dysmenorrhea?

Recommended Pharmacologic Treatment for Menstrual Pain

NSAIDs (nonsteroidal anti-inflammatory drugs) are the first-line pharmacologic treatment for primary dysmenorrhea, with specific agents like ibuprofen, naproxen sodium, and ketoprofen showing the strongest evidence for pain relief. 1

First-Line Treatment: NSAIDs

NSAIDs work by blocking cyclooxygenase enzymes, thereby inhibiting prostaglandin production—the primary driver of menstrual pain through uterine hypercontractility and reduced blood flow 2, 3. The evidence is compelling:

• NSAIDs are 4.37 times more likely to provide moderate-to-excellent pain relief compared to placebo, meaning if 18% of women on placebo get relief, 45-53% on NSAIDs will achieve the same 4
• Start NSAIDs at the onset of menstrual pain or bleeding, not after pain becomes severe 1
• Continue for 5-7 days as needed 5
• Specific effective agents include: ibuprofen, naproxen sodium, ketoprofen, mefenamic acid, and celecoxib 4, 3

Important Caveat

NSAIDs carry a 29% increased risk of adverse effects (gastrointestinal, neurological, headaches) compared to placebo—if 10% on placebo experience side effects, 11-14% on NSAIDs will 4. Counsel patients accordingly.

Second-Line Treatment: Hormonal Contraceptives

Combined hormonal contraceptives (CHCs) are equally effective as first-line therapy and should be offered based on patient preference, particularly if contraception is also desired 1, 2. They work by:

• Inhibiting endometrial development
• Decreasing menstrual prostaglandin production
• Reducing menstrual flow volume 3

Both NSAIDs and hormonal contraceptives can be initiated empirically without pelvic examination or invasive testing 1, 2.

Combination Therapy

If monotherapy fails, combine NSAIDs with hormonal contraceptives rather than switching between them 1. This addresses dysmenorrhea through complementary mechanisms.

Alternative Agents (Limited Evidence)

• Paracetamol (acetaminophen): Less effective than NSAIDs (OR 1.89 favoring NSAIDs) and should not be first-line 4
• Pelubiprofen 45 mg: A newer COX-2 selective NSAID showing superior efficacy to placebo in a 2026 trial, though not yet widely available 6
• COX-2 specific inhibitors (etoricoxib, celecoxib): No proven superiority over traditional NSAIDs for dysmenorrhea, with limited data 4

Critical Clinical Pitfalls to Avoid

1. Do not delay treatment waiting for definitive diagnosis—empiric therapy should begin immediately based on history alone 1, 2
2. Do not require pelvic examination before initiating treatment in adolescents or young women with typical primary dysmenorrhea 1
3. Reassess if no improvement after 3 months of compliant therapy—this signals possible secondary dysmenorrhea requiring imaging (ultrasound first, MRI if inconclusive) 1, 7
4. Watch for red flags suggesting secondary causes: pain not responding to NSAIDs/hormones, dyspareunia, abnormal bleeding patterns, or symptoms starting years after menarche 7, 1

Treatment Algorithm

1. Start with NSAIDs (ibuprofen, naproxen, or mefenamic acid) at pain onset, 5-7 days per cycle
2. If contraception desired or NSAIDs contraindicated: Start combined hormonal contraceptives
3. If inadequate response after 2-3 cycles: Add the other modality (NSAID + hormonal contraceptive)
4. If still no improvement with compliant use: Investigate for secondary causes with imaging

The evidence consistently supports this stepped approach, with the 2025 Canadian guideline 1 and 2020 ACOG review 2 providing the most current algorithmic frameworks, reinforced by the robust 2015 Cochrane meta-analysis of 80 trials 4.